Image Place holder

Filippo Veglia, PhD

Program: Immunology

Overview

  Dr. Veglia’s research interest is to investigate metabolic and molecular mechanisms of immune response to cancers. His current research efforts are focused on the study of the role of myeloid cells in thwarting immune and therapeutic responses to glioblastoma (GBM). His research is also focused on the design of novel strategies for the therapeutic targeting of myeloid cells.   


Associations

    • Gastrointestinal Oncology
    • Immunology
    • Neuro-Oncology
    • Immuno-Oncology
    • Immuno-Oncology

Education & Training

Research

  Dr. Veglia’s research interest is to investigate metabolic and molecular mechanisms of immune response to cancers. His current research efforts are focused on the study of the role of myeloid cells in thwarting immune and therapeutic responses to glioblastoma (GBM). His research is also focused on the design of novel strategies for the therapeutic targeting of myeloid cells.   

Publications

  • Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, Donthireddy L, Kossenkov A, Lin C, Fu S, Mulligan C, Nam B, Masters G, Denstman F, Bennett J, Hockstein N, Rynda-Apple A, Nefedova Y, Fuchs SY, Gabrilovich DI. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021 Mar.12(1):1717. Pubmedid: 33741967. Pmcid: PMC7979850.
  • Trizzino M, Zucco A, Deliard S, Wang F, Barbieri E, Veglia F, Gabrilovich D, Gardini A. EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. Sci Adv. 2021 Jan.7(3). Pubmedid: 33523892. Pmcid: PMC7806227.
  • Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021 Aug.21(8):485-498. Pubmedid: 33526920. Pmcid: PMC7849958.
  • Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G, Patel J, Bhargava V, Wilkinson P, Smirnov D, Sepulveda MA, Singhal S, Eruslanov EB, Cristescu R, Loboda A, Nefedova Y, Gabrilovich DI. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021 Apr.218(4). Pubmedid: 33566112. Pmcid: PMC7879582.
  • De Leo A, Ugolini A, Veglia F. Myeloid Cells in Glioblastoma Microenvironment. Cells. 2020 Dec.10(1). Pubmedid: 33374253. Pmcid: PMC7824606.
  • Ugolini A, Tyurin V, Tyurina Y, Tsyganov E, Donthireddy L, Kagan VE, Gabrilovich DI, Veglia F. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight. 2020 Aug.5(15). Pubmedid: 32584791. Pmcid: PMC7455061.
  • Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C, Nam B, Bennett J, Masters G, Guarino M, Kumar A, Nefedova Y, Vonderheide RH, Languino LR, Abrams SI, Gabrilovich DI. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. J Exp Med. 2019 Sep.216(9):2150-2169. Pubmedid: 31239386. Pmcid: PMC6719429.
  • Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, Ricciotti E, DiRusso C, Murphy ME, Vonderheide RH, Lieberman PM, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Lin C, Nefedova Y, Black P, Kagan VE, Gabrilovich DI. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019 May.569(7754):73-78. Pubmedid: 30996346. Pmcid: PMC6557120.
  • Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018 Feb.19(2):108-119. Pubmedid: 29348500. Pmcid: PMC5854158.
  • Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, Hashimoto A, Kapralov A, Amoscato A, Angelini R, Patel S, Alicea-Torres K, Weiner D, Murphy ME, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun. 2017 Dec.8(1):2122. Pubmedid: 29242535. Pmcid: PMC5730553.
  • Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017 Apr.45:43-51. Pubmedid: 28192720. Pmcid: PMC5449252.
  • Guerra-Pérez N, Aravantinou M, Veglia F, Goode D, Truong R, Derby N, Blanchard J, Grasperge B, Gettie A, Robbiani M, Martinelli E. Rectal HSV-2 Infection May Increase Rectal SIV Acquisition Even in the Context of SIVΔnef Vaccination. PLoS One. 2016 Feb.11(2):e0149491. Pubmedid: 26886938. Pmcid: PMC4757571.
  • Guerra-Pérez N, Frank I, Veglia F, Aravantinou M, Goode D, Blanchard JL, Gettie A, Robbiani M, Martinelli E. Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection. J Immunol. 2015 Mar.194(5):2415-2423. Pubmedid: 25624458. Pmcid: PMC4339396.
  • Ramakrishnan R, Tyurin VA, Tuyrin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, Johnson JJ, Zhang LM, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014 Mar.192(6):2920-2931. Pubmedid: 24554775. Pmcid: PMC3998104.
  • Martinelli E, Veglia F, Goode D, Guerra-Perez N, Aravantinou M, Arthos J, Piatak M, Lifson JD, Blanchard J, Gettie A, Robbiani M. The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection. J Acquir Immune Defic Syndr. 2013 Dec.64(4):325-331. Pubmedid: 23797688. Pmcid: PMC3815485.
  • Veglia F, Sciaraffia E, Riccomi A, Pinto D, Negri DR, De Magistris MT, Vendetti S. Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells. Infect Immun. 2011 Mar.79(3):1300-1310. Pubmedid: 21149590. Pmcid: PMC3067507.
  • Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, Rughetti A. HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. J Mol Med (Berl). 2011 Dec.89(12):1231-1240. Pubmedid: 21845448. Pmcid: PMC3218291.
  • Vendetti S, Davidson TS, Veglia F, Riccomi A, Negri DR, Lindstedt R, Pasquali P, Shevach EM, De Magistris MT. Polyclonal Treg cells enhance the activity of a mucosal adjuvant. Immunol Cell Biol. 2010 Oct.88(7):698-706. Pubmedid: 20585335.
  • Vendetti S, Riccomi A, Negri DR, Veglia F, Sciaraffia E, De Magistris MT. Development of antigen-specific T cells in mediastinal lymph nodes after intranasal immunization. Methods. 2009 Dec.49(4):334-339. Pubmedid: 19426804.

Grants

Title: Mechanisms of functional heterogeneity of tumor associated macrophages in glioblastoma
Sponsor: Ivy (Ben & Catherine) Fdtn
PI: Veglia, F.